Tango Therapeutics, Inc. (TNGX) fell 7.97% to $7.97, down $0.69, after announcing the pricing of an underwritten offering and concurrent PIPE expected to raise approximately $225 million.
The financing includes over 21 million shares at $8.66 each and pre-funded warrants, with closing anticipated on or about October 24, 2025. Earlier, the company reported positive interim data from its ongoing Phase 1/2 study of TNG462 and related programs, showing encouraging activity and tolerability in patients with MTAP-deleted cancers. The additional capital is expected to strengthen Tango's cash position and support its precision oncology pipeline, though the offering has sparked dilution concerns.
On Thursday, TNGX opened at $8.90, reached a high of $9.20, and a low of $7.85, compared to the previous close of $8.66 on the Nasdaq. Trading volume surged well above average levels. The stock's 52-week range is $7.80 - $12.45.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.